Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGMNUE)

• Drug Name: AM0010 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 3	[1]
Pancreatic ductal carcinoma	2C10.0	Phase 3	[2]
Non-small-cell lung cancer	2C25.Y	Phase 1	[3]
Renal cell carcinoma	2C90	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

• Cross-matching ID: TTD Drug ID: DMGMNUE

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-10 (IL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ilodecakin	DMDNHRA	Sarcoidosis	4B20.5	Phase 2	[6]
F-8-IL-10 fusion protein	DMBFPO1	Endometriosis	GA10	Phase 2	[7]
XT-150	DMCYM9Q	Knee osteoarthritis	FA01	Phase 2	[8]
AG019	DMEN2L7	Type-1 diabetes	5A10	Phase 1/2	[9]
Ankinara	DMZKC7S	Inflammatory bowel disease	DD72	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-10 (IL10)	TTT0Q1F	IL10_HUMAN	Modulator	[5]

References

• [1] ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of ARMO BioSciences.
• [6] Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
• [7] Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
• [8] Clinical pipeline report, company report or official report of Xalud Therapeutics
• [9] ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
• [10] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.